000136109 001__ 136109
000136109 005__ 20250923084431.0
000136109 0247_ $$2doi$$a10.1111/bcp.16157
000136109 0248_ $$2sideral$$a139065
000136109 037__ $$aART-2024-139065
000136109 041__ $$aeng
000136109 100__ $$aVinuesa-Hernando, José Manuel
000136109 245__ $$aInitiation of lipid-lowering therapy as primary prevention of cardiovascular disease in the elderly
000136109 260__ $$c2024
000136109 5060_ $$aAccess copy available to the general public$$fUnrestricted
000136109 5203_ $$aAims
This study aimed to analyse the initiation adherence phase to lipid-lowering therapy for primary prevention of cardiovascular disease in a Spanish population aged 70 years or older. The secondary objective was to identify the determinants of initiation and early discontinuation.
Methods
This was an observational study conducted in the CArdiovascular Risk factors for HEalth Service research (CARhES) cohort. People aged 70 and older with a first prescription of a lipid-lowering drug and without a previous major adverse cardiovascular event (MACE) were selected (2018–2021). Data on sociodemographics, clinical conditions, drugs and use of health services were collected from clinical and administrative electronic databases. The study population was classified into: non-initiation, early discontinuation (i.e., discontinuation after the first dispensing) and initiation with more than one dispensing. Their characteristics were compared. Determinants of initiation and early discontinuation were explored.
Results
Among the 15 019 people studied, 80.2% initiated the medication, 11.2% showed an early discontinuation and 8.6% were non-initiators. An older age or conditions such as dementia, diabetes or depression reduced the likelihood of initiation, while obesity and a high pharmacological burden increased it. People over 90 years of age or those prescribed a statin in combination were more likely to have an early discontinuation.
Conclusions
Non-initiation and early discontinuation are common among older people prescribed lipid-lowering drugs as primary prevention of cardiovascular disease for the first time. The presence of chronic pathologies other than cardiovascular ones should be considered when assessing whether or not to prescribe these drugs in the elderly.
000136109 536__ $$9info:eu-repo/grantAgreement/ES/DGA-GRISSA/B09-23R$$9info:eu-repo/grantAgreement/ES/ISCIII/PI22-01193
000136109 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000136109 590__ $$a3.0$$b2024
000136109 592__ $$a1.155$$b2024
000136109 591__ $$aPHARMACOLOGY & PHARMACY$$b138 / 352 = 0.392$$c2024$$dQ2$$eT2
000136109 593__ $$aPharmacology (medical)$$c2024$$dQ1
000136109 593__ $$aPharmacology$$c2024$$dQ1
000136109 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000136109 700__ $$0(orcid)0000-0001-7293-701X$$aAguilar-Palacio, Isabel$$uUniversidad de Zaragoza
000136109 700__ $$0(orcid)0000-0002-6671-5661$$aRabanaque, María José$$uUniversidad de Zaragoza
000136109 700__ $$aGarcía-Cárdenas, Victoria
000136109 700__ $$aLallana, María Jesús
000136109 700__ $$aGamba, Adriana
000136109 700__ $$0(orcid)0000-0002-7194-8275$$aMalo, Sara$$uUniversidad de Zaragoza
000136109 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000136109 773__ $$g90, 10 (2024), 2663-2672$$pBr. j. clin. pharmacol.$$tBRITISH JOURNAL OF CLINICAL PHARMACOLOGY$$x0306-5251
000136109 8564_ $$s997330$$uhttps://zaguan.unizar.es/record/136109/files/texto_completo.pdf$$yVersión publicada
000136109 8564_ $$s2223456$$uhttps://zaguan.unizar.es/record/136109/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000136109 909CO $$ooai:zaguan.unizar.es:136109$$particulos$$pdriver
000136109 951__ $$a2025-09-22-14:43:04
000136109 980__ $$aARTICLE